A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Public ClinicalTrials.gov record NCT05462106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Study identification
- NCT ID
- NCT05462106
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 304 participants
Conditions and interventions
Interventions
- Placebo (Study Part 1a) Biological
- ACI-24.060 at Dose A in Study Part 1a Biological
- ACI-24.060 at Dose B in Study Part 1a Biological
- ACI-24.060 at Dose C in Study Part 1a Biological
- ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b Biological
- Placebo (Study Part 2) Biological
- ACI-24.060 at Dose A in Study Part 2 Biological
- ACI-24.060 at Dose B in Study Part 2 Biological
- ACI-24.060 at Dose C in Study Part 2 Biological
- Placebo (Study Part 1b) Biological
- ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b Biological
Biological
Eligibility (public fields only)
- Age range
- 35 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2022
- Primary completion
- Mar 31, 2029
- Completion
- Mar 31, 2029
- Last update posted
- Jul 9, 2026
2022 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | Withdrawn |
| K2 Medical Research The Villages LLC | Lady Lake | Florida | 32159 | Recruiting |
| Charter Research, LLC | Orlando | Florida | 32803 | Recruiting |
| Headlands Horizons LLC | Orlando | Florida | 32819 | Not yet recruiting |
| Charter Research, LLC | The Villages | Florida | 32162 | Recruiting |
| Indiana University / IU Health | Indianapolis | Indiana | 46202 | Active, not recruiting |
| University of Kansas Medical Center Research Institute | Fairway | Kansas | 66205-2513 | Active, not recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Active, not recruiting |
| The Washington University | St Louis | Missouri | 63130 | Active, not recruiting |
| Flourish Research | Matthews | North Carolina | 28105 | Not yet recruiting |
| Neurology Clinical, P.C. | Cordova | Tennessee | 38018 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-2103 | Active, not recruiting |
| UT Health San Antonio | San Antonio | Texas | 78229 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05462106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05462106 live on ClinicalTrials.gov.